Yangli Pharma closes nine-figure RMB Series B round led by Qiming Venture Partners
Focused on developing first-in-class and best-in-class Class 1 innovative drugs with global intellectual property rights, with a focus on oncology and chronic disease therapeutics.
Recently, innovative drug R&D company Zhejiang Yangli Pharmaceutical Technology Co., Ltd. ("Yangli Pharma") announced the completion of a nine-figure RMB Series B financing round led exclusively by Qiming Venture Partners. The company's existing shareholders also include TF Capital, Hangzhou Capital, and Runzhang Venture Capital. Proceeds from this round will advance multiple clinical programs.
Founded in 2021 and headquartered in Hangzhou, Yangli Pharma operates with a China-based, globally competitive vision. The company focuses on developing first-in-class and best-in-class innovative Class 1 new drugs with global intellectual property rights, targeting oncology and chronic disease therapeutics, with multiple programs already in Phase I and Phase II clinical trials.
Yangli Pharma has assembled world-class drug innovation experts and management talent. Its core founding team holds degrees from Tsinghua University, UCLA, the State University of New York, West China Medical Center of Sichuan University (formerly West China University of Medical Sciences), and The University of Hong Kong.
Dr. Wei Sha, founder and president of Yangli Pharma, brings extensive industry experience. Prior to founding Yangli Pharma, she served as general manager of Taifeng Research Institute at Taifeng Pharmaceutical Group — a founding shareholder of Yangli Pharma — with comprehensive expertise spanning the entire drug development-to-commercialization lifecycle, laying a solid foundation for the company's innovative R&D and industrialization.
Dr. Zhaozhong Ding, co-founder and chairman, contributes over 30 years of drug development and management experience, bringing invaluable R&D leadership to Yangli Pharma.
Dr. Dong Fang, chief scientific officer, brings more than two decades of drug discovery and development experience. He contributed to the development of multiple approved oncology drugs including Lisaftoclax, Olverembatinib, Iruplinalkib, and Glasdegib, advanced dozens of IND applications in China and the United States, published over 40 peer-reviewed scientific papers, and holds more than 20 patents.
This strong talent team provides the core driving force for the company's innovative drug R&D. Yangli Pharma has already achieved significant progress across multiple innovative drug programs covering hypertension and various solid tumors. Clinical-stage assets include the highly selective aldosterone synthase inhibitor VB19055 and the small-molecule targeted agents TFX05, TFX06, and VB15. Preclinical small-molecule and small-nucleic-acid pipelines span oncology, hypertension, hyperlipidemia, and diabetes.
Yangli Pharma's outstanding performance in innovative drug development has earned numerous honors, including National High-Tech Enterprise, National Science and Technology SME, Zhejiang Province Innovative SME, 2024 Talent-Driven Demonstration Enterprise, and the ninth batch of "Dayun Talent" innovation and entrepreneurship projects.
Dr. Zhaozhong Ding, co-founder and chairman of Yangli Pharma, stated: "We are grateful for the consistent trust and support from our investors. Since our founding, the company has focused on addressing unmet clinical needs through differentiated, origin-driven R&D, following our 'In China, For Global' development philosophy. Leveraging our advantaged small-molecule and small-nucleic-acid technology platforms, we have built pipelines in oncology and chronic diseases. The successful completion of this financing round fully reflects investors' strong recognition of our pipeline's clinical competitiveness and market potential. This funding paves the way for our oncology programs to enter registrational trials and for our chronic disease products to achieve clinical validation. It marks Yangli Pharma's entry into a rapid growth phase, bringing us closer to innovative drug commercialization. We are committed to delivering value for our investors and improving health outcomes for patients as our mission."
Dr. Kan Chen, partner at Qiming Venture Partners and co-head of healthcare innovation, commented: "Yangli Pharma has built differentiated innovation from the ground up through forward-looking target selection and an efficient compound optimization platform, developing a portfolio of candidate molecules with high activity, high specificity, and excellent safety profiles. We believe that with the company's strong clinical development capabilities, these molecules will rapidly advance from pipeline to market, unlocking their tremendous clinical value and market potential to ultimately address urgent unmet needs for patients worldwide."
PAST HIGHLIGHTS
Qiming Perspectives | Qiming Venture Partners' Kan Chen: AI's Transformation of Biopharma Is Already Visible Qiming Honors | Qiming Venture Partners and Portfolio Companies Win Multiple Awards at 2029th Healthcare Investment Excellence Awards Qiming Honors | Qiming Venture Partners Selected for China Funds' Second Annual Private Equity & Venture Capital Excellence Cases
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since inception, Qiming has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, with more than 210 exiting through listings on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Hepalocure Pharmaceuticals, Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.